A composite (18)F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)
一种基于 (18)F-FDG PET/CT 和 HER2 组织的复合生物标志物,用于预测 HER2 阳性乳腺癌对新辅助帕妥珠单抗和曲妥珠单抗的反应 (TBCRC026)
期刊:Breast
影响因子:7.9
doi:10.1016/j.breast.2025.104432
Hennessy, Maeve A; Cimino-Mathews, Ashley; Carter, Jodi M; Kachergus, Jennifer M; Ma, Yaohua; Leal, Jeffrey P; Solnes, Lilja B; Abramson, Vandana G; Carey, Lisa A; Rimawi, Mothaffar; Specht, Jennifer; Storniolo, Anna Maria; Vaklavas, Christos; Krop, Ian; Winer, Eric; Denbow, Rita; Valero, Vincente; Wolff, Antonio C; Wahl, Richard L; Huang, Chiung-Yu; Stearns, Vered; Thompson, E Aubrey; Connolly, Roisin M